Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

Early Phase 1

10(83.3%)

N/A

1(8.3%)

Phase 1

1(8.3%)

12Total

Early Phase 1(10)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT07558850Not ApplicableRecruiting

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

Role: collaborator

NCT07490041Early Phase 1Recruiting

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

Role: collaborator

NCT07246096Early Phase 1Recruiting

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Role: collaborator

NCT07241468Early Phase 1Recruiting

An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease

Role: collaborator

NCT07185035Early Phase 1Recruiting

An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules

Role: collaborator

NCT07105735Phase 1Not Yet Recruiting

RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies

Role: collaborator

NCT06976437Early Phase 1Recruiting

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Role: collaborator

NCT06318533Early Phase 1Recruiting

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Role: collaborator

NCT06469190Early Phase 1Recruiting

An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

Role: collaborator

NCT06337474Early Phase 1Recruiting

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

Role: collaborator

NCT06613490Early Phase 1Recruiting

An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis

Role: collaborator

NCT06010472Early Phase 1Recruiting

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

Role: collaborator

All 12 trials loaded